CellGenix

What CellGenix does

CellGenix is a Freiburg, Germany-based manufacturer of high-purity recombinant human cytokines and growth factors sold as raw and ancillary materials to the cell and gene therapy industry. Founded in 1994 and operating with 51-100 employees, the company offers a portfolio of 62 specialized recombinant proteins spanning interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, Activin A, and TPO. Each SKU is offered in two quality grades — GMP (for further manufacturing use in clinical and commercial cell therapy production) and Preclinical (for preclinical ex vivo use) — with animal-component-free (51 SKUs) and xeno-free (10 SKUs) formulations to satisfy stringent regulatory requirements for Advanced Therapy Medicinal Products (ATMPs). Product specifications emphasize ultra-low endotoxin levels (e.g., ≤ 0.010 EU/µg and ≤ 0.025 EU/µg options), high purity (≥ 95% / ≥ 97%), and documented activity ranges, positioning CellGenix as a regulatory-grade supplier of critical raw materials.

CellGenix operates as a wholly-owned brand of Sartorius AG and is distributed exclusively through Sartorius's global e-commerce storefront (shop.sartorius.com) and enterprise field-sales channels, reaching cell and gene therapy manufacturers (CAR-T, NK cell, dendritic cell, iPSC/ESC, MSC, organoid, HSC developers), CDMOs, regenerative medicine companies, and academic/industrial life science researchers worldwide. Pricing is quote-based and not publicly disclosed, with standard pack sizes of 50 µg, 1 mg, and bulk formats (500 mL, 1000 mL). The company holds a registered CellGenix® trademark under Sartorius and competes on brand reputation, regulatory documentation depth, and domain specialization rather than on breadth of product categories. The founder, Felicia M Rosenthal, continues to serve as Co-founder, CEO & Managing Director.

Name

CellGenix

Website

https://cellgenix.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Short description

CellGenix® is a Freiburg-based manufacturer of 62 GMP- and Preclinical-grade recombinant human cytokines and growth factors, supplying regulatory-compliant raw materials to cell and gene therapy developers worldwide via Sartorius AG.

Ownership category

akta.pro rank

Product category

Cell Therapy Raw Materials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Cell therapy reagents
• Recombinant cytokines
• Growth factors manufacturing
• GMP-grade proteins
• Cell culture raw materials

Headquarters

HQ city

Freiburg

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Recombinant Protein Product Sales: CellGenix generates revenue through the sale of recombinant growth factors and cytokines to researchers and biopharmaceutical companies engaged in cell therapy, gene therapy, and regenerative medicine applications.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

CellGenix® manufactures and supplies 62 recombinant human growth factors and cytokines—including interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21, IL-1β), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, TPO, and Activin A—for use as raw and ancillary materials in cell and gene therapy manufacturing. Products are offered in both GMP (for further manufacturing use) and Preclinical (for preclinical ex vivo use) quality grades, with animal-component free and xeno-free formulations available, and are sold exclusively through the Sartorius distribution network.

Product overview

CellGenix® is a brand of recombinant human growth factors and cytokines for the cell and gene therapy market. The portfolio includes recombinant proteins such as interleukins (IL-2, IL-4, IL-7, IL-10, IL-15, IL-21), TNF-α, GM-CSF, FGF-2, EGF, PDGF-BB, TGF-β1, TPO, and Activin A. Products are available in GMP-grade (for further manufacturing use) and Preclinical-grade (for preclinical ex vivo use), targeting applications in cell and gene therapy, immune cell culture, stem cell biology, and regenerative medicine. The CellGenix® brand is distributed exclusively through Sartorius AG and focuses on xeno-free, animal-component-free formulations.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 62 specialized recombinant proteins available for cell and gene therapy applications

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• SartoriuscoreOEM/ Whitelabel/ Licensing PartnerCellGenix operates as a brand owned and distributed by Sartorius, a leading biopharmaceutical equipment and supplies company. All CellGenix products are sold through Sartorius's e-commerce platform and distribution network.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Miltenyi Biotec: Privately held German life science company that supplies recombinant cytokines, cell culture reagents, and instruments for cell and gene therapy manufacturing, with deep direct overlap with CellGenix's product portfolio and target customers (CDMOs and biopharma cell therapy developers).
• Bio-Techne (R&D Systems): Publicly traded US supplier of recombinant proteins (R&D Systems brand) including GMP-grade cytokines and growth factors used in cell therapy, regenerative medicine, and research — directly competing with CellGenix across both preclinical and GMP tiers.
• STEMCELL Technologies: Canadian supplier of cell culture media, reagents, cytokines, and tools for stem cell research and cell therapy development, with comparable specialty focus and customer overlap (academic and commercial cell therapy researchers, regenerative medicine developers).
• Akron Biotechnology: US-based supplier of ancillary materials, cytokines, and media for cell and gene therapy manufacturing, including GMP-grade recombinant proteins — a direct peer in the cell therapy raw materials niche with similar customer use cases.
• FUJIFILM Irvine Scientific: Supplier of cell culture media, reagents, and ancillary materials for cell therapy and regenerative medicine (including recombinant proteins), competing with CellGenix for GMP raw material wallet share at CDMOs and biopharma cell therapy developers.

Broad incumbents

• Cytiva: Global bioprocess supplier (formerly GE Healthcare Life Sciences) offering cell culture media, single-use technologies, and process services used by cell therapy manufacturers; overlaps with CellGenix on cell therapy raw materials but at much broader scale.
• Peprotech (Thermo Fisher Scientific): Peprotech was a specialist cytokine supplier acquired by Thermo Fisher; now positioned within Thermo Fisher's broader bioproduction portfolio, offering GMP and research-grade recombinant proteins that compete head-to-head with CellGenix while leveraging Thermo Fisher's larger scale and distribution.
• Lonza Group: Global CDMO and bioproducts company offering cell therapy manufacturing services plus cell and gene therapy raw materials and media; competes with CellGenix through its own recombinant protein/media portfolio and its CDMO relationships.

Others

• CellGenix (as Sartorius brand) - Sartorius AG: Parent company/distribution channel that owns the CellGenix® brand and sells all products through shop.sartorius.com — included as a parent/strategic relationship rather than a competitor, but adjacent given Sartorius's broader bioprocess portfolio.

Emerging players

• Sino Biological: China-based supplier of recombinant proteins, antibodies, and reagents that has expanded into GMP-grade cytokines for cell therapy — an emerging competitor that could pressure pricing as Chinese cell therapy manufacturing scales.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellgenix-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellGenix